2025
Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A, Group P. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer 2025, 131: e35871. PMID: 40558053, DOI: 10.1002/cncr.35871.Peer-Reviewed Original ResearchConceptsManagement of neuroendocrine neoplasmsPeritoneal metastasisNeuroendocrine neoplasmsConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsComplex clinical challengeLevel of evidenceCytoreductive surgerySurgical resectionSystemic therapyClinical managementClinical challengeLow incidenceModified Delphi techniquePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachMetastasisConsensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms
Su D, Brown L, Bansal V, Bakkila B, Concors S, Turaga K, Gunderson C, Bergsland E, Strosberg J, Halfdanarson T, Metz D, Kunstman J, Kunz P, Gangi A. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Annals Of Surgical Oncology 2025, 1-18. PMID: 40560496, DOI: 10.1245/s10434-025-17360-3.Peer-Reviewed Original ResearchPeritoneal metastasisCytoreductive surgeryConsensus guidelinesManagement of peritoneal metastasesClinical management of patientsManagement of PMManagement of patientsLevel of evidenceBackgroundNeuroendocrine neoplasmsSurgical resectionSystemic therapyNeuroendocrine neoplasmsClinical managementModified Delphi techniqueLow incidencePathway blockDisease gradeGrade 1Therapy conceptsHeterogeneous phenotypesFunctional syndromesMultidisciplinary approachRound IMetastasisNeoplasms
2024
Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms
Uhlig J, Nie J, Gibson J, Cecchini M, Stein S, Lacy J, Kunz P, Kim H. Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms. Scientific Reports 2024, 14: 30536. PMID: 39690170, PMCID: PMC11652651, DOI: 10.1038/s41598-024-81518-4.Peer-Reviewed Original ResearchConceptsGEP-NEN patientsGastroenteropancreatic neuroendocrine neoplasmsOverall survivalGEP-NENsTreatment patternsSystemic therapyNeuroendocrine neoplasmsAssociated with improved survivalLow-grade diseaseNational Cancer DatabaseLonger overall survivalSite-specific incidenceDisease specific factorsG3 NENSurgical resectionCancer DatabaseImproved survivalLow-stageCox regressionImprove outcomesPatientsIncidence increasesInternational guidelinesInvestigate incidenceSurvival
2021
Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors
Zhang JY, Kunz PL. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. JCO Oncology Practice 2021, 18: 258-264. PMID: 34652954, DOI: 10.1200/op.21.00240.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsFunctional statusPrimary sitePrevalence of NETsMetastatic neuroendocrine tumorsExtent of diseaseOngoing clinical trialsSomatostatin receptor statusIndividualized treatment planHeterogeneous clinical entityPace of diseaseConsideration of patientsPerformance statusSystemic therapyReceptor statusTumor characteristicsClinical entityTherapeutic optionsPathologic classificationClinical trialsTherapeutic decisionsDiagnostic modalitiesTreatment planDiseasePatients
2011
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: e595-e601. PMID: 22197234, DOI: 10.1016/j.ijrobp.2011.09.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNeoplasm Recurrence, LocalPancreatic NeoplasmsRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival RateConceptsIntensity-modulated radiotherapyLocal-regional control ratesPancreatic adenocarcinomaAdjuvant patientsDefinitive patientsControl rateSurvival rateGrade 3 late toxicityRecurrence-free survival ratesThree-dimensional conformal radiotherapyOverall survival rateProspective clinical trialsRecurrence-free survivalDurable disease controlPlanning target volumeGreater acute toxicityAcute toxicityLate toxicityOverall survivalSystemic therapyMedian agePancreatic cancerClinical trialsPrescription doseGrade 3
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply